7020 Background: MPM median OS does not exceed 13 months with pem/CDDP doublet.
US Intergroup phase II trial of gemcitabine/CDDP, with or without bevacizumab, gave an …

TPS7112 Background: MPM median OS does not exceed 13 months with pem/CDDP
doublet. US Intergroup phase II trial of gemcitabine/CDDP, with or without bevacizumab …

7500 Background: MPM median overall survival (OS) did not exceed 13 months with
pemetrexed-platinum doublet, with virtually no surviving patients at 5 years. Vascular …

Background: The aim of this open label phase II study (NCT00407459) was to assess the
activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined …

Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis,
linked to occupational asbestos exposure. Vascular endothelial growth factor is a key …

9004 Background. The RAMES Study (EudraCT Number 2016-001132-36) is a multicenter,
double-blind, randomized phase II trial exploring the efficacy and the safety of the addition of …

Background CBP501, a synthetic duodecapeptide, increases cisplatin influx into tumor cells
through an interaction with calmodulin enhancing cisplatin cytotoxicity, and effects cell cycle …

Introduction Previously published results from a randomized phase III study of pemetrexed
plus cisplatin in patients with malignant pleural mesothelioma (MPM) demonstrated a …

Background In a randomized phase III trial, pemetrexed plus cisplatin was associated with
improved survival compared with cisplatin alone for patients with malignant pleural …

8554 Background: Pemtrexed/cisplatin (PCisp) remains the standard frontline treatment for
advanced-stage MPM. However, a majority of patients are older and too fragile to tolerate …